Neurometrix Inc  

(Public, NASDAQ:NURO)   Watch this stock  
Find more results for NURO
0.000 (0.00%)
Sep 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 0.71 - 2.05
Open     -
Vol / Avg. 0.00/412,105.00
Mkt cap 10.04M
P/E     -
Div/yield     -
EPS -1.00
Shares 11.04M
Beta 0.63
Inst. own 14%
Oct 26, 2015
Q3 2015 NeuroMetrix Inc Earnings Release (Estimated) Add to calendar
Sep 10, 2015
NeuroMetrix Inc at Rodman & Renshaw Global Investment Conference - 3:25PM EDT - Add to calendar
Jul 22, 2015
Q2 2015 NeuroMetrix Inc Earnings Call - Webcast
Jul 22, 2015
Q2 2015 NeuroMetrix Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -98.22% -140.88%
Operating margin -272.61% -159.09%
EBITD margin - -156.45%
Return on average assets -38.36% -69.97%
Return on average equity -286.70% -146.78%
Employees 32 -
CDP Score - -


62 4th Ave
WALTHAM, MA 02451-7507
United States - Map
+1-781-8909989 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


NeuroMetrix, Inc. is a medical device company focused on the treatment of the neurological complications of diabetes. The Company managed its general purpose neurodiagnostic business to improve reimbursement and minimize customer erosion. The Company’s tools and therapies for addressing diabetic neuropathy represent a significant market opportunity. It’s both unique and substantial experience in devices to measure and alter peripheral nerve function, it addresses unmet needs through the development of proprietary medical devices. The Company intends to advance its objectives in the diabetic neuropathy market which include: Driving Commercial Adoption of its Proprietary Products for Diabetic Neuropathy in the United States. The Company’s two primary products that target the diabetic neuropathy market are: SENSUS and NC-stat DPNCheck. SENSUS is therapeutic device for relief of chronic, intractable pain. NC-stat DPNCheck, is a diagnostic test for Diabetic Peripheral Neuropathy or DPN.

Officers and directors

Shai N. Gozani M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer, Secretary
Age: 50
Bio & Compensation  - Reuters
Thomas T. Higgins Chief Financial Officer, Senior Vice President, Treasurer
Age: 63
Bio & Compensation  - Reuters
Francis X. McGillin Senior Vice President, General Manager - Consumer Wearables
Age: 54
Bio & Compensation  - Reuters
David E. Goodman M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Allen J. Hinkle M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Nancy E. Katz Independent Director
Age: 55
Bio & Compensation  - Reuters
Timothy R. Surgenor Independent Director
Age: 55
Bio & Compensation  - Reuters
David Van Avermaete Independent Director
Age: 63
Bio & Compensation  - Reuters